Sign Out
Usual dose: 500 mg to 1 g by intravenous administration every 8 hours depending on the type and severity of infection, the known or expected susceptibility of the pathogen(s), and the condition of the patient.
Exceptions: Febrile episodes in neutropenic patients: the dose should be 1 g every 8 hours.
Meningitis/Cystic Fibrosis: the dose should be 2 g every 8 hours.
When treating infections known or suspected to be caused by Pseudomonas aeruginosa, a dose of at least 1 g every 8 hours in adults (maximum approved dose is 6 g daily given in 3 divided doses) and a dose of at least 20 mg/kg every 8 hours in children (maximum approved dose is 120 mg/kg daily given in 3 divided doses) are recommended.
Regular sensitivity testing is recommended when treating Pseudomonas aeruginosa infections.
Meropenem (MERONEM) IV should be given as an intravenous bolus injection over approximately 5 minutes or by intravenous infusion over approximately 15 to 30 minutes (see Incompatibilities under Cautions for Usage and Storage for the reconstitution details). There is limited safety data available to support the administration of a 2g bolus dose.
Dosage Schedule for Adults with Impaired Renal Function: Dosage should be reduced in patients with creatinine clearance less than 51 mL/min, as scheduled as follows. (See Table 3.)
Click on icon to see table/diagram/imageMeropenem (MERONEM) IV is cleared by haemodialysis and haemofiltration; if continued treatment with Meropenem (MERONEM) IV is necessary, the unit dose based on the infection type and severity is recommended at the completion of the haemodialysis procedure to re-institute effective treatment.
There is no experience with peritoneal dialysis.
Use in Adults with Hepatic Insufficiency: No dosage adjustment is necessary in patients with hepatic impairment.
Elderly: No dosage adjustment is required for the elderly with normal renal function or creatinine clearance values above 50 mL/min.
Children: For infants and children over 3 months and up to 12 years of age the IV dose is 10 to 40 mg/kg every 8 hours depending on type and severity of infection, the known or suspected susceptibility of the pathogen(s), and the condition of the patient. In children over 50 kg weight, adult dosage should be used.
Exceptions: Febrile episodes in neutropenic patients: the dose should be 20 mg/kg every 8 hours.
Meningitis/Cystic Fibrosis: the dose should be 40 mg/kg every 8 hours.
Meropenem (MERONEM) IV should be given as an IV bolus over approximately 5 min or by intravenous infusion over approximately 15 to 30 minutes (see Incompatibilities under Cautions for Usage and Storage for the reconstitution details). There is limited safety data available to support the administration of a 40 mg/kg bolus dose.
There is no experience in children with renal impairment.
Method of Administration: Reconstitution and Compatibility: Meropenem (MERONEM) IV to be used for bolus intravenous injection should be reconstituted with sterile water for injection (10 mL for each 500 mg). This provides an approximate available concentration of 50 mg/mL. Reconstituted solutions are clear or pale yellow.
For intravenous infusion Meropenem (MERONEM) IV vials may be directly reconstituted with a compatible infusion fluid (as listed in Storage) and then further diluted with the compatible infusion fluid, as needed.
Freshly prepared solutions of Meropenem (MERONEM) IV should be used whenever possible. However, reconstituted solutions of Meropenem (MERONEM) IV maintain satisfactory potency at room temperature (15-25 degrees C) or under refrigeration (4 degrees C) as shown in Storage.
Meropenem (MERONEM) IV should not be mixed with or physically added to solutions containing other drugs.
Solutions of Meropenem (MERONEM) IV should not be frozen.
